About this trial
Fibromyalgia is the third most common musculoskeletal condition in terms of prevalence, after lumbar pain and osteoarthritis. Its prevalence is around 2-4 % and is more frequent in women than in men; the prevalence is highest in age the range of 40-60 years.
Eligibility criteria
Qualifiers
Patients fibromyalgia from both genders.
The duration of fibromyalgia is more than 6 month (all patients with history of cervical or lumbar pain) and following diagnosis of FM using the 2016 revised FM criteria, on the basis of the ACR-2010 criteria.
Their ages will be ranged from 25-35 years old.
They will be medically stable and have sufficient cognitive abilities that enable them to understand and follow instruction according to Montreal Cognitive Assessment (MoCA) >26.
Disqualifiers
Other Neurological diseases as stroke , multiple sclerosis, Parkinson's disease and motor neuron disease
Pacemaker
Spinal fusion-cervical or lumbar
Metal implants in the spine
Trial design
Treatments tested in this trial
- Aerobic Exercises
- Transcutaneous electrical nerve stimulation
Treatment groups
Sponsors and collaborators
Ahmed Alshimy
Lead sponsor
AlRyada University for Science & Technology
Sponsor institution